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Abstract
The newly purified extracellular polysaccharides (exopolysaccharides) from Parachlorella
kessleri (PCEPS) were evaluated on their antitumor and immunomodulatory effects in cell
culture and mouse colon carcinoma peritoneal dissemination model. In two-dimensional cell
culture, the PCEPS treatment inhibited cell growth of both murine and human colon carcinoma
cells in a dose- and time-dependent manner. In contrast, the growth of mouse splenocytes
(SPLs) and bone marrow cells (BMCs) were stimulated by the treatment with PCEPS. The
treatment with PCEPS also increased specific subpopulations of the cells in BMCs: antigen pre-
senting cells (CD19+ B cells, 33D1+ dendritic cells and CD68+ macrophage) and CD8+ cytotoxic
T cells. In three-dimensional spheroid culture, spheroid growth of CT26 cells co-cultured with
HL-60 human neutrophilic promyeloblasts and Jurkat cells (human lymphoblasts), but not THP-
1 human monocyte/macrophage was significantly attenuated by PCEPS treatment. In a mouse
CT26 colon carcinoma peritoneal dissemination model, intraperitoneal injection of PCEPS (10
mg/kg, twice per week) significantly attenuated the growth of CT26 colon carcinoma in synge-
neic mice. The present study suggests that PCEPS inhibits colon carcinoma growth via direct
cell growth inhibition and a stimulation of the host antitumor immune responses. Taken together,
the current study suggests that exopolysaccharides derived from Parachlorella kessleri contain
significant bioactive materials that inhibit colon carcinoma growth.
Introduction
In the United States, colon cancer is the second cause of cancer death and there is an estimated
at 95,270 new cases and 49,190 deaths in 2016 [1]. In the early stage of colon cancer, cancer is
removed by polypectomy or local excision and good prognosis is reserved for the patient
whose 5-year survival rate is 90%. However, survival rate declines to 70% and 13% for patients
diagnosed with regional (lymph node) and distant (liver, lung and peritoneum) metastasis,
respectively [2]. Although incidence and mortality of colon cancer have declined for the past
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tributes a significant portion of cancer-dependent mortality and morbidity.
Chlorella is a unicellular green algae and contains a variety of nutrients including amino
acids, carbohydrates, vitamins, minerals and dietary fibers, therefore it is taken as a nutritional
and functional dietary supplement worldwide [3]. In addition, it has been shown that whole
dried powder and/or water extracts of Chlorella vulgaris and C. pyrenoidosa have therapeutic
effects against several chronic diseases including hypertension [4, 5], hyperlipidemia [6, 7],
viral infections [8, 9] and various cancers [10–16]. Although these studies identify that chlo-
rella extract-dependent tumor growth inhibition is attributable to the stimulation of host anti-
tumor immune responses [17, 18], the molecular mechanism by which chlorella extract
stimulates immune responses is yet to be clear.
Recent studies also indicate that various microalgae produce a large amount of exopolysac-
charides [19]. Exopolysaccharides are composed of a variety of polymeric carbohydrate mole-
cules, such as alginate, cellulose, glucan, fucose, etc. and protect microbes from biotic and
abiotic stress, such as interspecific competition, temperature, light intensity, pH, heavy metal
stress, etc [20–23]. Although these exopolysaccharides produced by microalgae, such as cyano-
bacteria, are shown to exhibit apoptotic and antiviral activity in in vitro and in vivo [24, 25],
bioactivity derived from chlorella/parachlorella has not been rigorously studied. Since these
exopolysaccharides are presumably major components of whole chlorella water extract, it is of
interest to study the biological activities in the field of cancer prevention and therapy. Here we
report for the first time that exopolysaccharides derived from Parachlorella kessleri inhibit the
growth of murine colon carcinoma cells in vitro in cell culture and in vivo in mouse allograft
model via direct growth inhibition and stimulation of both neutrophilic promyeloblasts and
lymphoblasts.
Materials and methods
Animals
Wild-type female Balb/c mice were obtained from Charles River Laboratories International,
Inc. All mice were housed in a clean facility and held for 10 days to acclimatize. All experi-
ments were carried out under the approvals of Kansas State University Institutional Animal
Care and Use Committee (IACUC) and Institutional Biosafety Committee (IBC). All animal
experiments were done under strict adherence to IACUC protocols set by Kansas State Uni-
versity (Manhattan, KS).
Materials
Mouse colon carcinoma cell line CT26.CL25 (CRL-2639), human colon carcinoma cell lines
SW620 (CCL-227), HT29 (HTB-38), COLO 205 (CCL-222) and Caco-2 (HTB-37), human
neutrophilic promyeloblast cell line HL-60 (CCL-240), human monocyte/macrophage cell line
THP-1 (TIB-202) and human lymphoblast cell line Jurkat (TIB-152) were purchased from
American Type Culture Collection (ATCC, Manassas, VA). RPMI 1640 and Eagle’s minimal
essential medium (MEM) was obtained from Mediatech, Inc. (Manassas, VA). Macoy’s 5A
modified medium was purchased from Sigma (St. Louis, MO). Fetal bovine serum (FBS) was
from EQUITECH-BIO Inc. (Kerrville, TX). Penicillin-streptomycin stock was purchased from
Lonza Rockland, Inc. (Allendale, NJ). Lipopolysaccharides from Escherichia coli O111:B4 was
purchased from Sigma. Phycoerythrin (PE) conjugated antibodies targeting CD4 (H129.19),
CD8b (YTS156.7.7), CD19 (6D5), dendritic cells (DCs) marker (33D1), LY6G (1A8), CD68
(FA-11) and mouse IgG1, κ isotype (MOPC-21) were purchased from BioLegend (San Diego,
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CA). OxPAPC (TLR2 and TLR4 inhibitor) and Polymyxin B (TLR4 inhibitor) were from Invi-
troGen (San Diego, CA).
PCEPS preparation
Water extract from exopolysaccharides of Parachlorella kessleri (PCEPS) was obtained from
PANAC ADVANCE Co., Ltd. (Tokyo, Japan). The PCEPS was prepared by the propriety
method developed by the PANAC ADVANCE Co. Ltd. [26]. Briefly, culture media including
Parachlorella kessleri were centrifuged at 6,500 x g for 5 min. Supernatant was concentrated by
using an ultrafiltration membrane (SIP-1013, M.W. 6,000; Asahi Kasei Corp., Japan), then exo-
polysaccharides were purified by anion exchange resins. After re-concentration by the same
ultrafiltration membrane, the sample was freeze-dried to obtain crude exopolysaccharides of
Parachlorella kessleri. This crude extract was rehydrated at 4˚C overnight. After centrifugation
at 6,500 x g for 5 min, water soluble exopolysaccharides (PCEPS) containing supernatant was
freeze-dried and subjected for the current study. Carbohydrate composition of PCEPS was
analyzed by gas chromatography and found to be consisted of arabinose (4.7%), rhamnose
(4.0%), xylose (1.7%), mannose (22.5%) and galactose (67.1%). The average molecular weight
was determined by gel permeation chromatography and the major peak is shown to be approx-
imately 65,000Da [26]. The PCEPS was dissolved in PBS at a stock concentration of 1 mg/ml,
filtered through 0.22 μm disk filter (Midwest Scientific, Valley Park, MO) and the resultant fil-
trate was stored at -20˚C until use. To ensure a negligible amount of lipopolysaccharide (LPS)
contamination in this preparation, LPS levels in the final extract was determined by the Limu-
lus amebocyte lysate (LAL) assay (Pierc LAL Chromogenic Endotoxin Quantitation Kit,
Thermo Fisher Scientific, Waltham, MA). Assay results indicated that the final PCEPS prepa-
ration contained only very low levels of LPS or LPS-like immunoreactivity (average 0.1 ng per
1 μg PCEPS preparations, n = 3).
Cell culture
The CT26 murine colon carcinoma cell line, SW620 and COLO 205 human colon carcinoma
cell lines, HL-60, THP-1, and Jurkat cells were cultured with RPMI1640. The HT29 human
colon carcinoma cells were cultured with Macoy’s 5A modified medium. Caco-2 human colon
carcinoma cells were cultured with MEM. Each medium was supplemented with 10% v/v FBS
and 1% v/v Penicillin-streptomycin. These cells were cultured at 37˚C in a humidified air
atmosphere containing 5% CO2.
Effect of PCEPS on the growth of colon carcinoma cells, immune cells
and mesothelial cells in two-dimensional (2D) cell culture
The murine (CT26) (1,000 cells/well) and human (SW620, HT29, COLO 205 and Caco-2)
colon carcinoma cells (3,000 cells/well) were seeded into a 96 well plate with 100 μl growth
medium. After 24 hrs, the cells were treated with PCEPS. The dose-dependent effect of PCEPS
was evaluated by the cell growth treated with 1, 10 and 100 μg/ml PCEPS at 72 hrs after treat-
ment. The time-dependent effect of PCEPS was evaluated by the cell growth treated with
100 μg/ml PCEPS at 24, 48 and 72 hrs after treatment. The cell proliferation was evaluated
using 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as previ-
ously described [27]. PBS was used as the negative control. In addition, dose-dependency of
PCEPS (1–100 μg/ml for 48 hrs) on the growth of immune cell lines was evaluated as described
above by using human HL-60, THP-1 or Jurkat cells (1,000 cells/well).
The effect of PCEPS (24, 48 and 72 hrs treatment with 1–100 μg/ml PCEPS) on the growth
of mouse normal mesothelial cells (3,000 cells/well) was evaluated by MTT assay as described
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above. Mouse mesothelial cells were collected from Balb/c mice as described previously [28]
and cultured with RPMI-1640 medium supplemented 10% v/v FBS, 1% v/v penicillin-strepto-
mycin, 10 μM 2-mercaptoethanol, 400 μg/L hydrocortisone and Insulin-Transferrin-Sele-
nium-X (Thermo Fisher Scientific).
Effect of lipopolysaccharides on the growth of colon carcinoma cells,
immune cells in 2D cell culture
Lipopolysaccharides (LPS) are endotoxins found in the cell wall of Gram-negative bacteria
and cyanobacteria [29, 30]. It is reported that Lipid A-like molecules, which are the phos-
pholipid core of LPS, are immunologically detected in Chlorella sp. (strain NC64A) [31–33].
Therefore, it is conceivable that PCEPS may contain LPS-like molecules. In order to clarify
the differences between PCEPS and LPS, the effect of LPS on the growth of colon carcinoma
cell lines including murine CT26 cells (PCEPS sensitive), human HT29 cells (PCEPS sensi-
tive), and immune cell lines (HL-60, THP-1 and Jurkat) was evaluated by MTT assay as
described above.
PCEPS activation of splenocytes and born marrow cells in vitro
The effect of PCEPS on the cell proliferation of splenocytes (SPLs) and bone marrow cells
(BMCs) was evaluated by MTT assay in a 96-well plate. Balb/c mice were sacrificed by
decapitation under anesthesia. SPLs were collected from spleen and cultured with RPMI-
1640 supplemented 10% v/v FBS, 1% v/v penicillin-streptomycin, 20 μM 2-mercaptoetha-
nol. BMCs were collected from born marrow of hind leg and cultured with RPMI-1640 sup-
plemented 10% v/v FBS, 1% v/v penicillin-streptomycin. SPLs (5x105 cells/well) and BMCs
(2x105 cells/well) were cultured in a 96-well plate. The cell proliferation was evaluated with
dose-dependency (1, 10 and 100 μg/ml PCEPS for 48 hrs) and time-dependency (24, 48,
72 and 96 hrs treatment with 1 and 100 μg/ml PCEPS for SPLs, and 30 μg/ml PCEPS for
BMCs). As a positive control, 100 ng/ml LPS was treated. PBS was used as the negative
control.
Characterization of TLR-mediated splenocyte stimulation using
inhibitors
SPLs (5x105 cells/well) were seeded into a 96-well plate, then treated with either 15 μg/ml
OxPAC or 50 μg/ml Polymyxin B. After 30 min incubation, 10 μg/ml PCEPS or 100 ng/ml
LPS were added. Cell proliferation was evaluated by MTT assay at 48 hrs after treatment. PBS
was used as the negative control.
Analysis of PCEPS-induced BMCs activation using flow cytometry
Born marrow cells (5x106 cells) were seeded into a 6-well plate and incubated with 100 μg/ml
PCEPS for 48 hrs. In order to evaluate percentage of immune cell population, cells were immu-
nostained with anti-CD4 (helper T cells), CD8b (cytotoxic T cells), CD19 (B cells), DCs marker
(33D1, dendritic cells), LY6G (neutrophil) and CD68 (macrophage) antibodies. Mouse IgG
was used for the isotype control. The cell population was measured by flow cytometer (Moxi
Flow; ORFLO, Ketchum, ID). PBS and LPS (100 ng/ml) were used as the negative and positive
treatment control, respectively.
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Growth inhibitory effect of combination treatment by PCEPS and
immune cells on the growth of CT26 spheroid in in vitro three-
dimensional (3D) spheroid culture
In order to evaluate the combination effect by PCEPS and immune cells, a 3D spheroid assay
was performed as described previously with slight modifications [34]. Briefly, five hundred of
HL-60, THP-1 or Jurkat cells were mixed with 1.5% agarose dissolved in RPMI 1640 supple-
mented with 10% v/v FBS and 1% v/v penicillin-streptomycin. Fifty microliters of the mixture
were added in a 96-well plate and the agarose layer solidified by standing at room temperature
for 10 min. Then 1,000 of CT26 cells were seeded with growth medium on the agarose layer
(Day 0). PCEPS (30 μg/ml) was treated twice at Day 1 and Day 4. The image of spheroids was
taken by inverted microscope IX51 (Olympus America Inc., Center Valley, PA) equipped with
cellSens Dimension software (Olympus) at Day 8 and 10. The spheroid growth was evaluated
by spheroid area and was compared as a fold change to area at Day 8.
Analysis of gene expression in immune cells co-cultured with PCEPS-
treated CT26 cells in in vitro Transwell culture
The expression of CD11b, CD11c, and NADPH oxidase isoform (NOX2) in HL-60 and THP-
1 cells, and TNFα, IFNγ, IL-2 and granzyme b (GZMB) in Jurkat cells co-culture with PCEPS-
treated CT26 cells were evaluated by RT-qPCR. CT26 cells (1.5x104 cells) and HL-60, THP-1
or Jurkat cells (5x104 cells) were seeded in the Transwell inserts and corresponding 6-well
plates, respectively (Day 0). After 24 hrs (Day 1), PCEPS (30 μg/ml) was added into Transwell
inserts. Medium change and additional PCEPS treatment was carried out at Day 3 and Day 5.
At Day 6, immune cells in the 6-well plates were collected and total RNA was purified using
TRIzol reagent (InvitroGen). One step RT-qPCR was carried out using the iTaq Universal
SYBR Green One-Step Kit (Bio-Rad, Hercules, CA), and the reactions were conducted on the
StepOnePlus Real-Time PCR System (Applied Biosystems, Waltham, MA). The qPCR was
performed as follows: 45 cycles of 15 seconds at 95˚C, and 60 seconds at 60˚C. The results
were quantified by the comparative Ct method [35]. The sequences of primers used are
described in Table 1.
Table 1. Primers used for RT-qPCR.
Primer Sequence Size
Human Forward (5’-3’) GCAACCTCTCGTTTGACTGG 149 bp
CD11b Reverse (5’-3’) CTCCACTTTGGTCTCCGTCTG
Human Forward (5’-3’) CCTGTTGGCTTCTGTTCACC 157 bp
CD11c Reverse (5’-3’) GCTGTCGCCTTCTTTCTTCC
Human Forward (5’-3’) AATGGTGTGTGAATGCCCGAG 222 bp
NOX2 Reverse (5’-3’) GGATGGTTTTGGTGGAGGAAGTG
Human Forward (5’-3’) GCCAGAATGCTGCAGGACTT 63 bp
TNFα Reverse (5’-3’) GGCCTAAGGTCCACTTGTGTCA
Human Forward (5’-3’) AGGGAAGCGAAAAAGGAGTCA 64 bp
IFNγ Reverse (5’-3’) GGACAACCATTACTGGGATGCT
Human Forward (5’-3’) ATGAGACAGCAACCATTGTAGAATTT 87 bp
IL-2 Reverse (5’-3’) CACTTAATTATCAAGTCAGTGTTGAGATGA
Human Forward (5’-3’) TGCAGGAAGATCGAAAGTGCG 180 bp
GZMB Reverse (5’-3’) GAGGCATGCCATTGTTTCGTC
18S Forward (5’-3’) GAGGTTCGAAGACGATCAGA 315 bp
Reverse (5’-3’) TCGCTCCACCAACTAAGAAC
https://doi.org/10.1371/journal.pone.0175064.t001
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Treatment of tumor-bearing mice with intraperitoneal injection of PCEPS
The antitumor effect of PCEPS was evaluated in Balb/c mice with CT26 murine colon carci-
noma allograft. Mice were anesthetized with isoflurane and intraperitoneally injected with
2.5x105 CT26 cells suspended in 200 μl PBS. The intraperitoneal injection of PCEPS (10 mg/kg)
was carried out at 1 week after CT26 inoculation for 11 days (every other day, total 6 injections).
PBS was injected intraperitoneally as the control with the same schedule. The mouse body
weights were monitored every other day. Three weeks after CT26 injection, all mice were sacri-
ficed by decapitation under anesthesia and tumor nodules containing omenta and pancreases
were collected to examine tumor growth. The tumor nodules containing two organs were
weighed and fixed in 10% formalin for histological analysis. To evaluate the effect of PCEPS
alone on organ weights, omenta (only normal mice), pancreases (only normal mice), lungs, liv-
ers, spleens and intestines were also collected from PBS- or PCEPS-treated normal or CT26 cell
tumor-bearing mice and weighed. Since average weights of PBS- and PCEPS-treated mouse
organs were not different at all, tumor nodule weights were normalized by subtracting the aver-
age weights of the omentum (425.2 mg ± 37.3 mg) and the pancreas (161.1 mg ± 27.2 mg).
Flow cytometry analysis of immune cells in the ascites of PCEPS-treated
tumor-bearing mice
CT26 cell tumor-bearing mice were prepared as described above (n = 4). Immune cells in asci-
tes of PCEPS-treated tumor-bearing mice were collected at 2 days after the third treatment of
PCEPS. Five milliliter of saline was injected into the abdominal cavity using 22Gx1¼” Surflash
I.V. Catheter (Terumo Medical Corporation, Somerset, NJ) and ascites were collected via cath-
eter. This ascites collection was repeated one additional time. After removing red blood cells
using ACK lysing buffer (Lonza Walkersville, Inc., Walkersville, MD), leukocytes were immu-
nostained using anti-CD4, CD8b, CD19, 33D1, LY6G and CD68 antibodies, and their popula-
tion distributions were evaluated by flow cytometry. Mouse IgG was used for the isotype
control. PBS was used as the negative treatment control. To evaluate the effect of PCEPS on
the weights and appearances of various organs at midpoint of the PCEPS treatment (total 3
time treatments as compared to full scale treatment (total 6 time treatments)), tumor nodules
containing omenta and pancreases, lungs, livers, spleens and intestines were dissected from
PBS- or PCEPS-treated CT26 cell tumor-bearing mice, all organs were carefully observed and
their weights determined.
Analysis of PCEPS treatment-associated apoptosis of CT26 cell tumor
cells by immunohistochemistry
TUNEL assay was carried out using the DeadEndTM colorimetric TUNEL system (Promega,
Madison, WI) as previously described [36]. The average number of TUNEL positive cells in 10
random fields (n = 5–6) were calculated. Apoptotic cells in PCEPS-treated tumors were also
evaluated using anti-cleaved caspase-3 antibody (1;300 dilution, for 18 hrs at 4˚C, #9661, Cell
Signaling Technology, Danvers, MA) as previously described [37]. The average number of
anti-cleaved caspase-3 positive cells in 10 random fields (n = 5–6) was calculated.
Statistical analysis
All values are expressed as the mean ± standard deviation of mean. For all in vitro and in vivo
experiments, statistical significance was assessed by unpaired t-test or ANOVA followed by
Tukey’s test. All experiments were conducted with multiple sample determinations with sev-
eral samples (n = 3–5). Statistical significance was set at , P<0.05.
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Results
PCEPS treatment attenuated the growth of murine and human colon
carcinoma cells, but stimulated human immune cells in 2D cell culture
To clarify the effect of the water extract from the Parachlorella kessleri exopolysaccharide,
PCEPS, on the growth of colon cancer cells, a MTT assay was conducted. First, the specificity
of PCEPS’s effect on several colon cancer cells was evaluated. CT26 murine colon carcinoma
cells, SW620, HT29, COLO 205 and Caco-2 human colon carcinoma cells were treated with
PCEPS (1–100 μg/ml) for 72 hrs in 2D cell culture. The PCEPS treatment dose-dependently
(Fig 1A and 1B) and time-dependently (Fig 1C) attenuated the growth of CT26, HT29 and
Caco-2 colon carcinoma cells (P<0.05), but not SW620 and COLO 205 cells. The time-depen-
dent growth inhibition curves clearly indicated that CT26 cell growth was most sensitively
inhibited by the PCEPS treatment (Fig 1C). The growth of CT26 cells was decreased by treat-
ments with 10 (12.1% decrease, n.s.) and 100 μg/ml PCEPS (35.0% decrease, P<0.05) at 72 hrs
after the treatment (Fig 1A). Notably, the PCEPS treatment with 100 μg/ml inhibited the CT26
cell growth significantly at all three time points (24, 48 and 72 hrs), whereas the significant
growth inhibition was detected at 72 hrs after the treatment in both HT29 and Caco-2 cells
(Fig 1C). These results suggest that PCEPS treatment dose- and time-dependently attenuates
the growth of multiple colon cancer cells. In contrast, PCEPS dose-dependently stimulated the
growth of HL-60, THP-1 and Jurkat cells at 48 hrs after treatment (Fig 2). PCEPS treatment
did not show any effect on mouse normal mesothelial cell growth at doses of 1–100 μg/ml for
24–72 hrs. These results may suggest that PCEPS contains immune cell activating molecules as
well as cancer attenuating molecules which have negligible effect on normal cell growth.
LPS treatment bidirectionally altered the growth of murine and human
colon carcinoma cells, and slightly stimulated the growth of human
immune cells
As shown in Fig 3A, LPS treatment slightly but significantly increased the cell growth of CT26
murine colon carcinoma cells, but significantly attenuated the growth of HT29 human colon
carcinoma cells. Time course study showed that LPS treatment increased CT26 cell growth
even at 24 hrs after treatment and sustained the cell growth. On the contrary, HT29 cell growth
was significantly higher than the control at 24 hrs after treatment, but gradually decreased to
significantly low growth at the 72hrs time point (Fig 3B). The effect of LPS on cancer cell
growth is clearly different from the effect of PCEPS (Figs 1 and 2). LPS treatment slightly but
consistently stimulated the growth of all three types of immune cells (HL-60, THP-1 and Jur-
kat cells) in a dose-dependent manner (1–100 μg/ml for 48 hrs, Fig 3C). These results suggest
that LPS functions to control the growth of colon carcinoma cells differently from PCEPS.
PCEPS treatment stimulated the growth of splenocytes and bone
marrow cells
It has been reported that Chlorella vulgaris extract is capable of stimulating the growth of
immune cells [10, 11, 13, 15, 16]. In the present study, therefore, the growth stimulation effect
of PCEPS on immune cells was evaluated using SPLs and BMCs. PCEPS treatment (1–100 μg/
ml) significantly increased the growth of both SPLs (Fig 4A and 4B) and BMCs (Fig 4C and
4D) in a dose- and time-dependent manner. This PCEPS-dependent growth stimulation effect
was detected in lower concentrations at 1–100 μg/ml (Fig 4A and 4C). A positive control, LPS
also exhibited similar results in both SPLs and BMCs.
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PCEPS-dependent growth stimulation of splenocytes was inhibited by
TLR4 inhibitors
It has been reported that water extracts from C. vulgaris [17] and mushroom polysaccharide
Krestin [38] stimulate antitumor immune responses via TLR2. To evaluate the involvements
of TLRs in PCEPS-dependent growth stimulation of SPLs, SPLs were treated with either 10 μg/
ml PCEPS, or 100 ng/ml LPS (TLR4 agonist) in the presence/absence of 15μg/ml OxPAC
Fig 1. PCEPS dose- and time-dependently inhibited the growth of murine and human colon
carcinoma cells in 2D cell culture. PCEPS treatment dose-dependently (1–100 μg/ml for 72 hrs, A-B) and
time-dependently (24, 48 and 72 hrs treatment with 100 μg/ml PCEPS, C) attenuated the growth of CT26
murine colon carcinoma cells, HT29 and Caco-2, but not SW620 and COLO 205 human colon carcinoma
cells. The cell growth was evaluated by MTT assay. Results are presented as mean ± SD (n = 3). *, P<0.05
compared to PBS-treated control by Tukey’s test or t-test.
https://doi.org/10.1371/journal.pone.0175064.g001
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(TLR2 and TLR4 inhibitor) and 50μg/ml Polymyxin B (TLR4 inhibitor). The results are sum-
marized in Fig 5. The growth stimulatory effect by PCEPS was completely blunted by OxPAPC
(19.5% decrease, P<0.05) and polymyxin B (21.2% decreased, P<0.05). In the parallel control
study, treatment with the TLR4 agonist LPS significantly increased the growth of SPLs and its
growth was inhibited by OxPAPC and polymyxin B (13.96% decrease (P<0.05) in OxPAPC
and 26.75% decrease (P<0.05) in polymyxin B). These results suggest that both TLR2 and 4
are involved in PCEPS-dependent growth stimulation of splenocytes.
PCEPS treatment increased CD8+ T cell population in bone marrow cells
PCEPS treatment stimulated the growth of BMCs (Fig 4C and 4D). Detailed analysis of the
changes of immune cell populations in BMCs was performed using flow cytometry. As shown
in Fig 6, treatment with 100 μg/ml PCEPS increased CD4+ (118.1% increase as compared with
PBS control group), CD8+ (1,312.7% increase, P<0.05), CD19+ (74.9% increase), 33D1+
(563.9% increase), LY6G+ (12.4% increase) and CD68+ (81.0% increase) cells. Although all
tested cell populations were increased by PCEPS treatment, increase in only CD8+ cell popula-
tion was statistically significant. Increases of antigen presenting cell populations such as
CD19+ (B cells), 33D1+ (DCs) and CD68+ (macrophages) cells were large, but their increases
were not statistically significant due to large variations. In the LPS treatment group (100 ng/
ml), CD8+ (2,132.7% increase as compared to PBS control group, P<0.05), CD19+ (105.8%
increase, P<0.05), 33D1+ (1,494.4% increase, P<0.05) and CD68+ (120.9% increase, P<0.05)
cells were increased. In contrast, CD4+ (37.2 and 71.2% decrease as compared to PBS control
and PCEPS group, respectively, P<0.05) and LY6G+ (52.8 and 58.0% decrease, P<0.05) were
significantly decreased. In the BMCs treated with LPS, antigen presenting cell population was
notably increased compared with that of PCEPS-treated group. These results may suggest that
PCEPS treatment increases cell populations related to the adaptive immune system.
PCEPS treatment enhanced HL-60 and Jurkat cell antitumor activities in
the spheroid growth of CT26 cells in vitro
The in vitro spheroid assay is an effective and a reproducible method to mimic a tumor micro-
environment, therefore it is useful to evaluate the effect of therapeutics prior to an animal
Fig 2. PCEPS dose-dependently stimulated the growth of immune cells. The dose-dependent effect of
PCEPS (1–100 μg/ml for 48 hrs) on the growth of HL-60, THP-1 and Jurkat cells was evaluated by MTT
assay. Results are presented as mean ± SD (n = 3). *, P<0.05 compared to PBS-treated control by Tukey’s
test.
https://doi.org/10.1371/journal.pone.0175064.g002
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study [34]. As shown in Fig 7A, co-culture with HL-60, THP-1 and Jurkat cells did not attenu-
ate the spheroid growth of CT26 cells in the PBS-treated group. Although the treatment with
30 μg/ml PCEPS alone also did not show any growth inhibition effect, the spheroid growth of
CT26 cells was significantly attenuated with the combination of the PCEPS treatment with the
co-culture of HL-60 (P<0.05 as compared with PCEPS alone and HL-60 cell alone co-cultured
CT26 spheroids) or Jurkat cell (P<0.05 as compared with PCEPS alone and Jurkat cell alone
co-cultured CT26 spheroids). Although the combination treatment with PCEPS and THP-1
cells significantly decreased the transparency in the peripheral area of the spheroid, this combi-
nation treatment did not decrease the spheroid’s size (Fig 7B). Morphological analysis of co-
cultured immune cells in the spheroid assay revealed that PCEPS treatment alone or co-cultur-
ing with CT26 spheroids only slightly modified the morphologies of HL-60, THP-1 and Jurkat
cells (Fig 7C). However, their morphologies were drastically changed by the combination
treatment with PCEPS in the presence of a CT26 spheroid. These morphological analyses may
suggest that PCEPS triggers immune cell differentiations and that the PCEPS effect is signifi-
cantly enhanced in the presence of cancer cells. Further analysis of immune cells in the pres-
ence of PCEPS-treated CT26 cells was conducted by measuring gene expression using
Fig 3. Effect of LPS on the growth of colon carcinoma cells and immune cells. (A-B) CT26 and HT29 colon
carcinoma cells were treated with LPS dose-dependently (1–100 μg/ml for 72 hrs, A) and time-dependently (24, 48 and
72 hrs treatment with 100 μg/ml LPS, B). (C) Human immune cells (HL-60, THP-1 and Jurkat cells) were treated with
LPS dose-dependently (1–100 μg/ml for 48 hrs). The cell growth was evaluated by MTT assay. Results are presented
as mean ± SD (n = 5). *, P<0.05 compared to PBS-treated control by Tukey’s test or t-test.
https://doi.org/10.1371/journal.pone.0175064.g003
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Transwell culture system (Fig 8). While only CD11c expression was significantly upregulated
in HL-60 cells, both CD11b and CD11c expression were significantly upregulated in THP-1
cells co-cultured with PCEPS-treated CT26 cells. Analysis of genes related to the reactive oxy-
gen species production and T cell activation revealed that significant upregulation of NOX2 in
HL-60 and THP-1 cells, and TNFα, IFNγ and GZMB in Jurkat cells were observed as com-
pared to PBS- or PCEPS alone-treated immune cells and immune cells co-cultured with PBS-
treated CT26 cells. It is strongly suggested that PCEPS assists immature immune cells to differ-
entiate into antitumor immune cells, thereby inhibiting CT26 cell tumor spheroid growth.
Intraperitoneal injection of PCEPS attenuated the growth of CT26
murine colon carcinoma in a peritoneal dissemination model
To evaluate an antitumor effect of PCEPS in vivo, 10 mg/kg PCEPS was injected into the peri-
toneal cavity of the CT26 cell tumor-bearing mice (n = 6/group, 2.5x105 cells). The treatment
was started one week post tumor cell injection and was given every other day for 11 days. As
shown in Fig 9A, the PBS control group developed a large number of 1–5 mm diameter tumor
nodules in the entire greater omentum, whereas the PCEPS-treated group developed only a
few visible tumor nodules. Average tumor weight (mg) in PCEPS-treated group (937.4
±1,350.5, P<0.05) was significantly smaller than that of PBS treatment group (3,861.6
±1,335.2) (Fig 9B). As shown in S1 and S2 Figs, PCEPS treatment did not influence organ
Fig 4. PCEPS dose- and time-dependently stimulated the growth of murine splenocytes and bone marrow cells in cell culture.
PCEPS treatment dose-dependently (1–100 μg/ml for 48 hrs) and time-dependently (24, 48 72 and 96 hrs treatment with 1–100 μg/ml
PCEPS) stimulated the growth of mouse SPLs (A and B) and BMCs (C and D). SPLs and BMCs were also treated with 100 ng/ml LPS as a
control. The cell growth was evaluated by MTT assay. Results are presented as mean ± SD (n = 3). *, P<0.05 compared to PBS-treated
control by Tukey’s test or t-test.
https://doi.org/10.1371/journal.pone.0175064.g004
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weight in normal and tumor-bearing mice. Although the spleen weight increased in tumor-
bearing mice compared with that of normal mice (S1 Fig), spleen weight increase is commonly
observed in tumor bearing mice as tumors develop. Since PCEPS treatment induced increases
of various leukocyte numbers in BMCs in vitro (Fig 6) and morphology changes in cultured
immune cells (Fig 7), it suggests that PCEPS treatment may influence the host immune system.
To clarify this hypothesis, immune cell populations in ascites collected from PBS- or PCEPS-
Fig 5. Evaluation of the TLRs involvement in the PCEPS-dependent growth stimulation of splenocytes
in cell culture. SPLs were stimulated with 10 μg/ml PCEPS and 100 ng/ml LPS (TLR4 agonist) in the presence
of 15 μg/ml OxPAC (TLR2 and TLR4 inhibitor) and 50 μg/ml Polymyxin B (an inhibitor of LPS-induced TLR4
activation). Inhibitory effect of TLR inhibitors on SPL growth was evaluated by MTT assay at 48 hrs after the
treatment. *, P<0.05 compared to PBS-treated SPLs in each group by Tukey’s test.
https://doi.org/10.1371/journal.pone.0175064.g005
Fig 6. PCEPS treatment increased various immune cell populations in primary cultured mouse bone
marrow cells. BMCs were collected from mouse hind legs and were seeded into 6-well plates and treated
with 100 μg/ml PCEPS and 100 ng/ml LPS for 48 hrs. These BMCs were labeled with either anti-CD4, CD8b,
CD19, 33D1, LY6G or CD68 antibodies and relative quantities were analyzed by flow cytometry. PBS and
LPS were used as the negative and positive control, respectively. Results are presented as mean ± SD
(n = 3). *, P<0.05 compared to PBS control group by t-test. †, P<0.05 compared to PCEPS-treated group by t-
test.
https://doi.org/10.1371/journal.pone.0175064.g006
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Fig 7. PCEPS treatment attenuated the spheroid growth of CT26 colon carcinoma cells in 3D cell
culture in the presence of various immune cells. The CT26 cells were grown on a U-shaped agar matrix
which contains HL-60, THP-1 or Jurkat cells (Day 0). The PCEPS (30 μg/ml) was treated twice at Day 1 and
Parachlorella kessleri exopolysaccharide inhibits colon cancer growth
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treated tumor-bearing mice were investigated by flow cytometry. As shown in Fig 10, PCEPS
treatment increased CD4+ (40.2% increase as compared to PBS control group), CD8+ T lym-
phocyte (18.9% increase), CD19+ B cell (700.3% increase, P<0.05) and CD68+ macrophage
(47.8% increase) populations. In contrast, 33D1+ dendritic cell (43.5% decrease) and LY6G+
neutrophil (61.2% decrease) populations were decreased as compared to PBS-treated group.
Significant increase of CD19+ B cell in PCEPS-treated mice suggest that PCEPS treatment may
induce an adaptive immune response to the PCEPS. Immunohistochemical analysis of apopto-
tic cells in tumor nodules clearly suggested that the PCEPS treatment significantly increased
apoptotic cells in PCEPS-treated CT26 cell tumors compared to PBS-treated tumors (Fig 11).
These results clearly indicate that PCEPS treatment is effective in inhibition of colon carci-
noma growth in mice.
Discussion
Although chlorella and its extracts are food sources with high nutritional value, increasing
publications indicate that chlorella extracts are novel sources for therapeutics of various dis-
eases including cancers [3]. Most of the previous medical studies have used water extracts of C.
Vulgaris and C. Pyrenoidosa among multiple chlorella species [4–18]. Nevertheless, Parachlor-
ella, a genus of green algae that contains two species (P. Kessleri and P. beijerinckil) and belongs
Day 4. The size of the spheroid was measured at Day 8 and Day 10 (A). The values are presented as fold
change of spheroid size compared with Days 8 and 10 (Day10/Day 8). Results are presented as mean ± SD
(n = 5). *, P<0.05 compared to PBS-treated CT26 cells alone group by Tukey’s test. †, P<0.05 compared to
same group in PBS-treated group by t-test. (B) Typical pictures of spheroid in each group. Scale bar in each
picture represents 100 μm. (C) Typical morphologies of HL-60, THP-1 and Jurkat cells in agar matrix of each
treatment group. Scale bar in each picture represents 20 μm.
https://doi.org/10.1371/journal.pone.0175064.g007
Fig 8. PCEPS treatment increased expression of differentiation marker and reactive oxygen-related genes in immune
cells co-cultured with PCEPS-treated CT26 colon carcinoma cells in Transwell cell culture. The HL-60, THP-1 or Jurkat
cells in the bottom well of 6-well plates and CT26 cells in the insert of Transwell were co-cultured (Day 0). The PCEPS (30 μg/
ml) treatment was provided at Day 1, Day 3 and Day 5. Total RNA was collected from individual immune cells in the 6 well plate
at Day 6. Gene expression in HL-60 (A), THP-1 (B) and Jurkat (C) cells were measured by RT-qPCR. Results are presented
as mean ± SD (n = 4) of relative quantity. a-d, P<0.05 between different characters in each target gene by t-test.
https://doi.org/10.1371/journal.pone.0175064.g008
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to chlorellales, has been limitedly used in medicinal fields. However, recent discoveries indi-
cate that Parachlorella kessleri produces relatively large amounts of exopolysaccharides which
coat the outside of their algae cell membrane [39]. Although these exopolysaccharides play a
protective role against environmental stress and chemical toxins [21, 23], their functions in
medicinal chemistry is yet to be clear. Accordingly, we have prepared a water extract from par-
tially purified exopolysaccharides of Parachlorella Kessleri,termed PCEPS and evaluated their
antitumor and immune modulatory abilities in in vitro and in vivo.
The effect of PCEPS on the growth of murine and human colon cancer cell lines was evalu-
ated in both 2D and 3D cell cultures. PCEPS moderately, but significantly attenuated the
growth of CT26 murine colon carcinoma cells in 2D cell culture (Fig 1A and 1C). This attenu-
ating effect of PCEPS on the colon carcinoma was also observed in human cell lines, HT29 and
Caco-2, but not in SW620 and COLO 205 (Fig 1B and 1C). Both HT29 and Caco-2 cell lines
Fig 9. PCEPS treatment significantly attenuated the growth of CT26 cell tumors in mouse peritoneal
cavity. The CT26 cells (2.5x105) suspended in 200μl PBS was inoculated in peritoneal cavity of Balb/c mice.
The PCEPS treatment (10 mg/kg, IP, every other day) was started one week after cancer cell inoculation and
carried out 11 days (a total of 6 times injections). All mice were sacrificed three weeks after CT26 cell injection.
(A) Macroscopic view of typical peritoneal cavity in PBS and PCEPS-treated mice. Scale bar in each picture
represents 5 mm. (B) Average tumor weight in each treatment group was presented in the bar graphs. Results
are presented as mean ± SD (n = 6). *, P<0.05 as compared with the tumor weight in PBS-treated group by t-
test.
https://doi.org/10.1371/journal.pone.0175064.g009
Fig 10. PCEPS treatment caused changes in leukocyte populations in ascites of CT26 cell tumor-bearing
mice. The CT26 cells (2.5x105) suspended in 200μl PBS was inoculated in the peritoneal cavity of Balb/c mice.
The PCEPS treatment (10 mg/kg, IP, every other day) was started one week after cancer cell inoculation and
continued for a total of 3 times. Ascites was collected two days after last treatment. Leukocytes in the ascites were
labeled with anti-CD4, CD8b, CD19, 33D1, LY6G and CD68 antibodies and their populations were analyzed by
flow cytometry. PBS was used as the negative control treatment. Results are presented as mean ±SD (n = 4).
*, P<0.05 compared to PBS control group by t-test.
https://doi.org/10.1371/journal.pone.0175064.g010
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have an epithelial origin, whereas both SW620 and COLO 205 are established from colon car-
cinoma-derived metastatic tumors [40, 41]. These different origins of each cell line may
describe the different responsiveness to PCEPS. In contrast, this growth inhibition effect was
not detected in 3D spheroid culture (Fig 7). It is known that 3D culture condition more closely
mimics natural tumor growth than that in 2D culture condition [34]. For this reason, 3D cul-
ture methods such as clonogenic assay [42–44] and spheroid assay [34] have been applied to
the evaluation and screening of novel therapeutics for cancer treatments. Present study results,
therefore, may suggest that the cytotoxic antitumor effect of PCEPS alone is not strong enough
to inhibit 3D spheroid growth of CT26 cells within a short time. In addition, limitation of the
MTT assay in monitoring cell proliferation should be considered since MTT assay is known to
be influenced by metabolic status of cells [45].
In contrast, PCEPS treatment clearly attenuated spheroid growth of CT26 cells when they
were co-cultured with HL-60 or Jurkat cells (Fig 7). These two cell lines are frequently used as
typical immune cells alternative to mature immune cells collected from peripheral blood. For
example, Jurkat cells were used for the evaluation of the IL-2-induced granzyme B production,
which is released from cytotoxic T cells and natural killer cells and induces apoptosis in adja-
cent malignant cells [46, 47]. Likewise, HL-60 cells were used for the determination of neutro-
phil-specific antibacterial activity using neutrophil-like cells differentiated from HL-60 [48,
49]. Accordingly, it is thought that the co-culture of the cancer cells with the above mentioned
immune cells conducted in the present study mimicked a tumor microenvironment closer to
biological conditions than the single spheroid culture of cancer cells. Therefore, results suggest
that the PCEPS-induced antitumor effect in the presence of immature immune cells, either
neutrophilic promyeloblasts (HL-60 cells) or lymphoblasts (Jurkat cells) in 3D spheroid cul-
ture is attributable to the collaborative effect of both CT26 cells and immune cells. These
Fig 11. PCEPS treatment significantly increased the number of apoptotic cells in CT26 cell tumors in
mouse peritoneal cavity. (A) Microscopic images of immunohistochemistry for TUNEL assay. (B) The TUNEL
positive cells were significantly increased in the PCEPS-treated tumors. (C) Microscopic images of immunohisto-
chemistry by anti-cleaved caspase-3. (D) The cleaved caspase-3 positive cells were also significantly increased in
the PCEPS-treated tumors. Results are presented as mean ±SD (n = 5–6). *, P<0.05 as compared to the level of
the PBS-treated control tumors by t-test.
https://doi.org/10.1371/journal.pone.0175064.g011
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results further suggest that PCEPS induces functional differentiations of these immature
immune cells in collaboration with cancer cells. Indeed, morphologies of these immature cells
have drastically enlarged and became dendritic cell-type structure in the spheroid culture (Fig
7C). This PCEPS induced functional differentiations of these immune cells co-cultured with
cancer cells was also confirmed by the changes of neutrophil, monocyte/macrophage or T cell
activation-associated mRNA level (Fig 8). This PCEPS-induced local differentiation/activation
of two types of immune cells is a potentially useful mechanism in targeting cancer therapy
applicable to both primary and metastatic cancer. To the best of our knowledge, this is the first
study to report that PCEPS stimulates differentiations of two types of immature immune cells
thereby, inducing cell death of cancer cells in co-culture.
The finding of immune stimulatory effect of PCEPS in the 3D spheroid assay was also sup-
ported from a different angle. Cell culture studies with primary cultured mouse SPLs and
BMCs indicated that PCEPS stimulates the growth of both cell types via either TLR2 or TLR4
signaling (Figs 4 and 5). Furthermore, flow cytometry analysis revealed that PCEPS treatment
increased various leucocytes including antigen presenting cells and T lymphocyte, particularly
CD8+ T cell population in BMCs (Fig 6). These results, along with the 3D tumor spheroid
assay, suggest that the PCEPS treatment may stimulate both growth and differentiation of mul-
tiple leucocyte populations via either TLR2 or TLR4 signaling. It is reported that LPS-like mol-
ecules are found in chlorella sp. (strain NC64A) [31, 32]. It appears that cell membranes of
green algae contain lipopolysaccharides similar to those of LPS [31, 32]. Although the PCEPS
preparation used for this study was found to contain a very low level of LPS or LPS-like mole-
cules (0.1 ng per 1 μg PCEPS), the effects of LPS on the growth of colon carcinoma cells and
immune cells were evaluated (Figs 1–3) and compared with those by the PCEPS. As shown in
the Fig 3, high concentrations of LPS (100 μg/ml) stimulated the growth of CT26 cells and all
three types of immune cells. Although extents of the growth stimulation of immune cells by
PCEPS were higher than those by LPS, both molecules stimulated immune cell growth. How-
ever, PCEPS and LPS showed opposite reactions against CT26 cells (PCEPS decreased (Fig 1),
but LPS significantly increased cell growth (Fig 3)). In addition, bone marrow cell responses to
PCEPS/LPS (Fig 6) indicate that 33D1 positive dendritic cells responded to only LPS. It is
apparent that PCEPS is functionally different from LPS in CT26 cell/dendritic cell growth
stimulations. These results clearly indicate that biological activities of PCEPS are different
from those of LPS and LPS-like molecule’s contribution to PCEPS’s activities appears to be
negligible. However, to further clarify the biological activities of PCEPS, determination of the
structural identify of the active compound(s) in PCEPS is essential.
The solid inhibitory ability against colon carcinoma cells in both 2D and 3D cell culture
studies and the robust growth and differentiation stimulatory actions in various leucocytes
with negligible cytotoxicity compelled in vivo efficacy of PCEPS. In the present mouse study, a
relatively small amount of PCEPS (10 mg/kg dissolved in PBS) was injected intraperitoneally
every other day starting one week after cancer cell inoculation. As shown in Figs 9 and 11, this
PCEPS treatment significantly attenuated the growth of murine colon carcinoma cells by
inducing apoptosis in tumor cells as compared to the PBS-treated mice in a peritoneal dissemi-
nation model. Taken together, these results suggest that PCEPS effectively inhibited the growth
of colon carcinoma cells directly and indirectly through immune cell activations in a tumor
microenvironment, thereby significantly attenuating colon tumor growth in mice. The major
antitumor mechanism by which PCEPS inhibited tumor growth in mice appears to be the
stimulation of antitumor immune function since 3D tumor spheroid growth was significantly
inhibited only in the presence of neutrophilic promyeloblasts, HL-60, and lymphoblasts, Jurkat
cells. This speculation is supported by the PCEPS-dependent increases of various adaptive
immune cells in ascites (Fig 10) and upregulations of reactive oxygen species-related genes in
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HL-60, and T cell cytotoxicity-related cytokines, such as TNFα, IFNγ and GZMB in Jurkat
cells (Fig 8). However, a detailed mechanism that inhibits tumor growth in vivo must be clari-
fied by another study.
In conclusion, our novel Parachlorella kessleri extract, PCEPS, can moderately inhibit
murine colon carcinoma cells, but significantly stimulate the growth of primary cultured
mouse SPLs and BMCs. PCEPS treatment also significantly increased CD8+ T cell population
in primary cultured mouse BMCs. In a 3D spheroid culture, PCEPS treatment significantly
attenuated the spheroid growth of murine colon carcinoma cells in the presence of neutro-
philic promyeloblasts, HL-60, or lymphoblasts, Jurkat cells. In a murine colon carcinoma peri-
toneal dissemination model with syngeneic mice, PCEPS treatment markedly attenuated
tumor growth. Although, further studies are required to confirm the in vivo safety of PCEPS
by formal pharmacokinetics, pharmacodynamics, and multispecies toxicity studies, these data
show that PCEPS could be a useful bioactive agent that can stimulate antitumor immune cells.
Supporting information
S1 Fig. Average organ weights in PBS- or PCEPS-treated normal or CT26 cell tumor-bear-
ing mice at full scale PCEPS treatment (total 6 time treatments). Omenta (only normal
mice), pancreases (only normal mice), lungs, livers, spleens and intestines in normal or tumor-
bearing mice in each treatment group was dissected and weighed. Results are presented as
mean ± SD (n = 6). , P<0.05 as compared to the PBS-treated group by t-test.
(TIF)
S2 Fig. Average tumor and organ weights in PBS- or PCEPS-treated normal or CT26 cell
tumor-bearing mice at midpoint of the PCEPS treatment (total 3 time treatments).
Tumors, lungs, livers, spleens and intestines in normal or tumor-bearing mice in each treat-
ment group was dissected and weighed. Results are presented as mean ± SD (n = 4). , P<0.05
as compared to the PBS-treated group by t-test.
(TIF)
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